Day: December 19, 2025

PASCAGOULA, Miss., Dec. 19, 2025 (GLOBE NEWSWIRE) — HII’s (NYSE: HII) Ingalls Shipbuilding division has been selected by the U.S. Navy to design and build the future small surface combatant (SSC) ship, leveraging the proven design of the Ingalls-built Legend-class national security cutter (NSC). With a proven track record of building complex ships, and having the available facility capacity, Ingalls shipbuilders will once again engage in construction activities alongside its destroyer and amphibious ship shipbuilding lines where the national security cutters were built, using the same sequence of build. “We look forward to supporting the Navy on this critical program,” said Chris Kastner, HII president and CEO. “Speed matters, and the NSC ship design is stable and produceable and will lead to predictable schedules. I have...

FRIENDSWOOD, Texas, Dec. 19, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on Dec. 15, 2025, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 83 employees covering an aggregate of 139,494 shares of common stock as an inducement material to their entering into employment with Castle Biosciences. The RSUs were granted pursuant to the Company’s 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares vesting on the first anniversary of the applicable vesting commencement date, and the balance vesting annually thereafter in three equal installments, subject to the employee’s continued service through...

Class A Ordinary Shares Will Begin Trading on a Post-Consolidation Adjusted Basis onDecember 23, 2025 BEIJING, Dec. 19, 2025 (GLOBE NEWSWIRE) — Cheer Holding, Inc. (NASDAQ: CHR) (“Cheer Holding,” “we” or the “Company”), a leading provider of next-generation mobile internet infrastructure and platform services, today announced that it intends to effect a share consolidation of its ordinary shares at a ratio of 1 post-split Class A ordinary share for every 50 pre-split ordinary shares (the “Share Consolidation”) so that every fifty (50) shares issued and outstanding will be combined into one (1) share. The Share Consolidation will become effective at 4:05 p.m. (New York time) on December 22, 2025 (the “Effective Time”).  The Company’s Class A ordinary shares will continue to be traded on the Nasdaq Capital Market (“Nasdaq”) under...

On 19 December 2025, AS Ekspress Grupp entered the contract for the acquisition of 100% of shares in the traffic training platform Liikluslab Baltic OÜ. Liikluslab Baltic OÜ is a platform for traffic education materials (liikluslab.ee) founded in 2019, which has expanded rapidly and offers services to both private individuals and driving schools. Liikluslab Baltic has two subsidiaries: the traffic learning environment Teooria OÜ (teooria.ee) and Liikluslab Tervis OÜ, which deals with health certificates for driving license applicants. The purpose of the acquisition is to grow the digital business and expand into a new business area. Strategically, the acquisition supports Ekspress Grupp’s long-term goal of increasing revenues from digital subscriptions and services and creates an opportunity for international expansion. After the...

MSD declines to exercise option for EVX-B2 development Evaxion is now able to out-license EVX-B2 to another partner Evaxion maintains its strong belief in EVX-B2, which has shown to be protective against Gonorrhea in preclinical studies There is no impact on Evaxion’s cash runway which extends to the second half of 2027COPENHAGEN, Denmark, December 19, 2025 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has been informed that MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA) will not exercise its option for Evaxion’s Gonorrhea vaccine candidate EVX-B2. Consequently, Evaxion retains global rights to EVX-B2 and will look for another potential licensing partner. Earlier this year MSD exercised its option on a separate Evaxion vaccine...

12:00 London, 14:00 Helsinki, 19 December 2025 – Afarak Group SE (“Afarak” or “the Company”) (LSE: AFRK, NASDAQ: AFAGR) AFARAK GROUP SE´S 2026 FINANCIAL REPORTING CALENDAR Stock Exchange Release Afarak Group SE (“Afarak” or the “Company”) will publish its financial results as follows: – Full Year 2025 Results on Friday 27 February 2026 – Annual Report 2025 during the week commencing 23 March 2026 – Report for six months ending 30 June on Friday 14 August 2026 The Company’s Annual General Meeting is scheduled to be held on Tuesday 9 June 2026. A separate notice of General Meeting will be published prior to the meeting in 2026. Production reports for Q1 2026 will be issued by 30 April 2026, and for Q3 2026 will be issued by 30 October 2026. Helsinki, December 19,...

NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Roxmore Resources Inc. (CSE: RM; OTCQX: GARLF), a Canadian resource company, has qualified to trade on the OTCQX® Best Market. Roxmore Resources Inc. upgraded to OTCQX from the OTCID™ Basic Market. Roxmore Resources Inc. begins trading today on OTCQX under the symbol “GARLF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors. For companies listed on a qualified international exchange, streamlined market standards enable them to utilize their home...

LONDON and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, announced that Executive Chairman and Founder, Gabriele Cerrone and the OKYO management team will ring the Opening Bell at the Nasdaq MarketSite in Times Square, New York today. The ceremony will be held from 9:15 AM to 9:45 AM ET, and celebrates OKYO’s ongoing advancements in innovative treatments, including its lead candidate urcosimod, a lipid-conjugated chemerin peptide agonist targeting the ChemR23 G-protein-coupled receptor. The company’s novel approach aims to address a significant unmet need in...